Windlas Biotech Q3FY26: Record revenue at Rs 233 cr, 20% YoY growth
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech reported 9MFY26 revenue of Rs 666 cr, up 19% YoY, marking 12 consecutive quarters of record revenue. Q3FY26 revenue grew 20% YoY to Rs 233 cr. 9M EBITDA rose 16% to Rs 79 cr with margins at 11.9%. Reported PAT grew 13% to Rs 50 cr; EPS at Rs 24.02. Adjusted PAT (ex ESOP) jumped 28% to Rs 60 cr. CDMO vertical led with 20% 9M growth, exports up 29%. Q3 EBITDA and PAT dipped as margins compressed.
Strong topline momentum with 12 straight record quarters. Q3 margin pressure and 4% PAT dip are watch points despite solid 9M performance.